Cabozantinib + Nivolumab as First-Line Treatment in Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cabozantinib and Nivolumab as First-Line Treatment in Advanced Renal Cell Carcinoma
Expert Rev Anticancer Ther 2021 Aug 27;[EPub Ahead of Print], MG Vitale, C Nasso, M Oltrecolli, C Baldessari, M Fanelli, M Dominici, R SabbatiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.